Background. Both capillary hemangioblastoma (CHB) and pheochromocytoma (PCC) are rare, usually benign tumours occurring sporadically or as part of familial cancer syndromes. The genetic background of most of the inherited cases is well established, but the molecular causes of sporadic cases remains poorly characterized. To better understand the molecular mechanisms of CHB and PCC pathogenesis, we analysed the genetic and epigenetic alterations of the p16 and p14 genes at the CDKN2A locus.
INTRODUCTION
The cyclin-dependent kinase inhibitor 2A (CDKN2A) locus on the human chromosome 9p21 encodes two important cell cycle regulators -the p16 (CDKN2A/INK4a) and p14 (ARF) genes. The tumour suppressor p16 is an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4 and CDK6) and is a significant component of the retinoblastoma protein (pRB) regulatory pathway (1) . The ARF protein encoded by p14 is an important player in the p53 pathway; it is responsible for the stabilization and increased functionality of p53 (1) . Inactivation of this locus through genetic deletion or aberrant promoter DNA methylation has been observed in various malignancies, including gliomas (2-4) and pheo-chromocytomas (5, 6) . Moreover, the evidence obtained using a mouse model (7) strongly supports involvement of CDKN2A locus in the development of pheochromocytoma (PCC). Our previous study (8) , conducted by means of immunohistochemistry, identified a frequent loss of the p16 protein expression in gliomas, PCC and capillary hemangioblastomas (CHB). We continued our studies on the pathogenesis of PCC and CHB (8, 9) by analysing genetic losses and DNA hypermethylation in the promoter region of the p16 and p14 genes at the CDKN2A locus. For comparison, cases with glioma -a highly malignant tumour of the central nervous system (CNS) -were included into the study.
Capillary hemangioblastoma (CHB) is a benign hypervascular tumour most frequently located in the CNS and in some cases in the retina (10) . About 20-30% of all CHBs occur as part of familial von Hippel-Lindau (VHL) disease caused by inherited mutation of the VHL gene, but sporadic cases are also common among the patients (10, 11) . Pheochromocytoma (PCC) is a rare tumour arising from neural crest-derived chromaffin cells in the adrenal medulla. The majority (80−90%) of PCCs are sporadic cases, but they may occur also as part of several cancer syndromes, including VHL disease (12) . Mutations of the VHL gene have been observed not only in familial cases of CHB and PCC, but also are detectable in sporadic tumours (13) . However, recent data have pointed to the involvement of other genes in the pathogenesis of CHB and PCC, especially in sporadic cases (14, 15) .
Glioma is the most prevalent tumour of the brain, which accounts for 2% of all cancers and results in a disproportionately high share of cancer morbidity and mortality (16) . Gliomas are derived from glial cells (astrocytes, oligodentrocytes and ependymocytes) and comprised of astrocytomas, glioblastoma multiforme (GBM), oligodendrogliomas, and ependymomas. GBM is the most common (accounting for 60-70% of all malignant gliomas) and the most malignant variant of glioma, with most of the patients dying within 1 year after diagnosis (16, 17) . Tumourigenesis of glioma is a complex process, and the p16-pRb and ARF-p53 cell cycle arrest pathways play a prominent role in glial transformation (16, 17) .
Aberrant DNA methylation in the promoter region of tumour suppressor genes (TSGs) is an early and ubiquitous process in human cancer, which has a deleterious effect on gene expression and normal cellular functions. Altered epigenetic modifications contribute to many of the hallmarks of cancer cells, including the loss of cell cycle control due to inactivation of major regulatory proteins, such as p16 and ARF (18) . Our previous studies (19) (20) (21) and data of other researchers have revealed a frequent inactivation of the genes on the CDKN2A locus through aberrant promoter methylation in a wide spectrum of tumours, including carcinomas of lung, bladder, head and neck, while data on DNA methylation status on this locus in human PCC and CHB are very scarce.
We extended our previous studies on the molecular pathways of hemangioblastoma and pheochromocytoma and analysed the genetic and epigenetic alterations of the p16 and p14 genes on the CDKN2A locus. For comparison, a set of cases with glioma, a highly malignant tumour of the brain, was included into the study.
MATERIALS AND METHODS

Patients and samples
The study analysed 8 cases of PCC, 8 cases of CHB and 28 cases of glioma, mainly diagnosed as glioblastoma (75%). The main characteristics of the study group are presented in Table 1 . The study was approved by the Lithuanian Ethics Committee.
Paraffin-embedded tumour specimens were obtained from the archives of the National Centre of Pathology, Lithuania. All good-quality CHB and PCC samples and representative samples of glioma collected at the National Centre of Pathology (NPC) during 2002-2005 were included into the study. For the analysis of genetic and epigenetic alterations, genomic DNA was extracted from the specimens by digestion with proteinase K, followed by standard phenol-chloroform purification and ethanol precipitation. DNA extracted from leukocytes of healthy controls (n = 2) and DNA from the cancer cell lines T24 (from American Type Culture Collection, USA), U87, U138, U251 and U373 (kindly provided by Prof. Tom Bohling, HUSLAB Helsinki, Finland) were used as the controls in TSG hypermethylation studies.
Methylation analysis of the p16 and p14 genes Methylation-specific PCR (MSP; 22) was used for the analysis of the methylation pattern in the 5' region of the p16 and p14 genes (Fig. 1A) . Genomic DNA (1 µg) was exposed to bisulphite modification as described elsewhere (20) . Briefly, 1 µg of genomic DNA was denatured with 3 M NaOH for 15 min at 37 °C and then exposed to bisulphite modification with 2.3 M sodium metabisulphite and 10 mM hydroquinone (all chemicals from Sigma-Aldrich Inc, Gillingham, Dorsel, UK). Exposure to sodium metabisulphite was carried out at 50 °C for 16 h. Modified DNA was purified with the Wizard DNA Clean-up System (Promega, Madison, WI), desulphonated with 3 M NaOH and precipitated with ethanol.
PCR primers specific to methylated (M) and unmethylated (U) sequences within the 5' region of the p16 and p14 genes were designed according to published sequences (22, 23) and purchased from biomers.net (Ulm Donau, Germany).
The MSP reaction mixture for 25 µl of total reaction volume contained 1-2 µl of bisulphite-modified DNA template, PCR buffer, 0.4 mM of each deoxynucleotide triphosphate, 2.5 mM of MgCl 2 , 1% of dimethylsulfoxide, sense and antisense primers at the final concentration of 6 ng/µl and 1.25 U of AmpliTaq Gold polymerase (Applied Biosystems, Piscataway, NJ). The PCR was performed in a thermocycler (Mastercycler ep gradient S, Eppendorf AG, Hamburg, Germany) under the following conditions: hot start at 95 °C for 10 min, 35 to 37 cycles at 95 °C for 45 s, annealing at 64 or 66 ºC (p16 and p14, respectively) for 45 s, 72 °C for 45 s, and the final extension at 72 °C for 10 min. The PCR product was analyzed on non-denaturing polyacrylamide gel after ethidium bromide staining. The gene was recorded as being hypermethylated when MSP amplification products were detected in both reactions with the primers for M and U sequence, or for M sequence only (Fig. 1A) .
Bisulphite-modified DNA from leukocytes of healthy donors was used as a negative control and in vitro methylated DNA (SssI methylase, New England BioLabs Inc, Beverly, MA) or DNA from cancer cell lines as a positive control. Non-template (water) controls were included in each PCR.
Gene deletion analysis by differential PCR
Cases negative in the MSP reaction (neither methylated nor unmethylated MSP product detected) were analysed by means of the differential PCR (dPCR; (2)) to confirm the occurrence of genetic deletion. Negative MSP reactions were mainly observed in the p16 gene region, thus only this gene was included in the dPCR analysis. The sequence covering the p16 gene region analysed in MSP was included in the dPCR analysis. As a reference, the sequence for the gene β-actin was used (2). The PCR reaction was conducted in 25 µl of the total reaction volume that contained 1 µl of non-modified DNA template, PCR buffer, 0.4 mM of each deoxynucleotide triphosphate, 2.5 mM of MgCl 2 , primers for the analysed gene and β-actin at final concentrations of 1 µM, and 1 U of AmpliTaq Gold polymerase (Applied Biosystems). DNA was amplified with 36 cycles of PCR and analysed on polyacrylamide gel after ethidium bromide staining. Samples positive for β-actin reaction, but negative for p16 or showing a week signal were considered as having a deletion of the p16 locus (Fig. 1B) .
Statistical analysis
Two-sided Fisher's exact test was used for a comparison of categorical variables. Odds ratios (OR) and the exact or Mantel-Haenszel 95% confidence intervals (CI) for two binomial samples were calculated. P < 0.05 was considered as statistically significant. 
RESULTS
Genetic and epigenetic inactivation of the p16 and p14 genes Aberrant promoter methylation of the p16 gene (Table 2) was observed in two cases with CHB (2/8; 25%) and two cases with PCC (2/8; 25%). Similarly, the gene p14 promoter was hypermethylated in three cases with CHB (3/8; 37%) and four cases with PCC (4/8; 50%). In total, the prevalence of hypermethylation in these tumours was 25% for the p16 gene and 41% for the p14 gene. One case with CHB (1/8; 12.5%) was negative in the p16 MSP reaction and was analysed by dPCR. Occurrence of the genetic deletion was proved by this method. In total, 69% (11/16) of the cases with CHB or PCC were identified either with genetic (deletion) or epigenetic (DNA methylation) alterations of genes on the CDKN2A locus.
In gliomas, the frequency of hypermethylation was 35% (9/26) in the p16 gene and 26% (7/27) in the p14 gene. Hypermethylation of these genes was more prevalent (Table 2) in low-grade gliomas (astrocytomas, oligoastrocytomas, oligodendrogliomas) as compared to high-grade tumours -glioblastomas. However, this difference did not reach statistical significance (p = 0.13 for the p16 gene and p = 0.33 for the p14 gene). Deletion of the p16 gene was detected in one case (17%) with low-grade glioma and in 25% (5/20) of high-grade gliomas. In total, 64% (16/25) of gliomas had at least one alteration of the analysed locus. Interestingly, hypermethylation of the genes in the CDKN2A locus or p16 deletion were identified in all but one cases with low-grade glioblastoma, showing the significance of this locus in this type of malignancies.
In glioma cell lines, hypermethylation of the p16 gene was detected in the cell line U87, while no hypermethylation of the gene p14 was observed in any of glioma cell lines analysed. Leukocyte DNA from healthy controls was negative for methylation in both genes.
A comparison of benign tumours (PCC and CHB) with gliomas did not reveal statistically significant differences in the frequencies of epigenetic or genetic changes of the CDKN2A locus (Fig. 2) . However, hypermethylation of the p16 gene was most frequent in low-grade gliomas (67%; p = 0.06 as compared with other tumours), while the p14 gene hypermethylation was predominant in PCC (50%; p = 0.19 as compared with other tumours).
Associations to clinical and molecular variables
No significant associations were observed between the genes' methylation or mutation and clinical-demographic variables of the cases in the total group of tumours. A separate analysis of gliomas as the most homogeneous and numerous group of the study revealed some important tendencies. Hypermethylation of p14 was prevalent in female patients with glioma and not found in men (p = 0.059; OR 12.39; CI 0.62-246.32). The proportion of those who (8) survived longer than one year after the diagnosis was higher among cases with p16 hypermethylation or mutation than in patients without these alterations (83% vs 50%). The genetic and epigenetic alterations of the CDKN2A locus were correlated with the p16 and p53 protein expression assessed by means of immunohistochemistry (IHC) in our previous study (8) on the same set of cases. In PCC and CHB, neither p16 nor p53 expression were detected. In gliomas, only 7% of cases with p16 deletion or hypermethylation showed a strong IHC signal (IHC3) for p16, while 40% of cases without genetic or epigenetic inactivation of p16 expressed p16 abundantly (Fig. 3A) . In gliomas, p14 hypermethylation almost equally occurred in cases with an aberrant and normal p53 expression (29% and 25%, respectively), while p16 alterations were more prevalent among p53 wild-type cases (73% vs 50% as compared with p53-mutant cases; Fig. 3B ).
When alterations in all tree genes (p16, p14 and TP53) were considered, 82% of gliomas were positive for at least one of these biomarkers (Fig. 2) . In contrast, aberrant expression of p53 was rare in benign tumours (PCC and CHB) and did not improve the diagnostic value of the molecular system of biomarkers analysed in our study.
DISCUSSION
In the present study, we report a frequent inactivation of genes on the CDKN2A locus through aberrant methylation or genetic deletion in the rare and usually benign human neoplasms -pheochromocytoma and hemangioblastoma. At least one alteration of this locus was observed in 75% of PCC and in 62.5% of CHB, but was also frequent (64%) in gliomas -malignant tumours of the brain. The study provides first data on the frequency of aberrant methylation in the promoter region of the p16 and p14 genes in CHB.
The CDKN2A locus on chromosome 9p21 encodes two important regulators from the pRB and p53 pathways -the p16 (CDKN2A/INK4a) and p14 (ARF) genes. The p16 gene encodes an inhibitor of the cyclin-dependent kinases CDK4 and CDK6; inactivation of this inhibitor causes an uncontrolled proliferation of cancer cells. ARF protein regulates p53 stability in response to aberrant cell growth induced by oncogenic stimuli and, like the p16 protein, is also frequently inactivated during tumourigenesis. These two genes have different promoters and exon 1, but share the exons 2 and 3 that are transcribed in alternative reading frames (1) . In cancer cells, both promoters can be inactivated through aberrant DNA methylation independently of each other. However, deletion of the 9p21 locus can inactivate both genes, or even include additional TSGs residing in this locus.
Previous studies (6, 24) , including our own data (8), revealed a frequent loss of p16 expression in gliomas and PCCs. Also, our recent study (8) for the first time showed a frequent loss of p16 expression in CHB. Both events, genetic deletion and promoter hypermethylation, are shown to be involved in the inactivation of p16 expression in gliomas and PCCs. Nakamura et al. (2) detected a frequent (13/50; 26%) deletion of the p16 gene in glioblastomas, but no such deletion was found in low-grade gliomas (2, 25) . Similarly, in our study, deletion of the p16 gene was detected in 25% of high-grade gliomas, but was rare (1/6) in low-grade gliomas. Genetic deletion of the p16 locus occurred also in one case with CHB, but was not observed in PCC.
Numerous studies of various human tumours have supported the observation that p16 expression can be lost associations between aberrant p53 expression and alterations of the p16 or p14 genes due to the aberrant DNA methylation in the promoter of the gene. In our study, aberrant promoter methylation occurred in 25% of CHBs and in 25% of PCCs. This epigenetic alteration was also frequent (35%) in gliomas, and predominantly occurred in low-grade tumours (67%). In glioblastomas, the published frequency of p16 promoter hypermethylation varies considerably among studies -from less than 10% up to 90% (2, (26) (27) (28) . In agreement with our data, frequent hypermethylation of p16 in low-grade gliomas has been shown in several studies (29, 30) . In PCC, our data on the moderate frequency of p16 hypermethylation are in line with other two studies (5, 6) in which the rates of this alteration were 24% and 35.5%, respectively. In general, our present study on the inactivation of p16 through genetic deletion or aberrant promoter methylation is in good agreement with our previous data (8) on p16 expression. In gliomas, 14 out of 15 cases with the genetic or epigenetic inactivation of p16 had also reduced the expression of the p16 protein. Interestingly, all cases with CHB and PCC showed a reduced or no p16 staining in our previous study (8) , despite DNA methylation or mutation status, showing the importance of additional regulators for the p16 expression in these tumours. Similarly, the study of Muscarella et al. (6) showed a reduced p16 expression in all but one cases with PCC, while the genetic and epigenetic alterations occurred only in a set (68%) of the cases. In CHB, no data on the frequency of genetic deletions or promoter hypermethylation of the p16 gene have been published up to date.
The reported frequencies of p14 promoter methylation in gliomas range from 20 to 40% (3, 4, 29, 31) . Furthermore, aberrant methylation of p14 was shown to be associated with the progression of astrocytic tumours. In PCC, only one study (32) analysed p14 hypermethylation, and no such studies have been conducted in CHB. Kiss et al. (32) reported frequent (73%; 32/44) p14 methylation using an MSP assay, but a quantitative analysis revealed low levels of the gene methylation. In the present study, p14 gene promoter methylation was frequent in PCCs (50%) and CHBs (37.5%), but less abundant in gliomas (26%).
ARF, encoded by p14, is a protein of the p53-regulated pathway. When the results of our previous study (8) were considered in combination with the present data, we noted an exclusive nature of the occurrence of p53 alterations and p14 hypermethylation. In PCC and CHB, where no aberrant expression of p53 was detected by means of immunohistochemistry, aberrant methylation of p14 was a frequent event that occurred in 44% of cases. In contrast, in glioblastomas where p53 alterations were obviously predominant (65%), p14 hypermethylation was not a common event (20%). The exclusive nature of the inactivation of genes from the same pathway is a well known phenomenon. As an example, in gliomas He et al. (31) observed a negative correlation between p14 methylation and p53 protein expression. Moreover, Watanabe et al. (3) have provided an evidence that alternative alterations of the p53 and p14 genes can serve as a significant predictor of a shorter progression-free survival in glioma. No such association with the survival of patients was detected in our study.
In summary, when all data on the genetic and epigenetic alterations of the CDKN2A locus were combined with the results on p53 expression, at least one alteration in the CDKN2A locus and p53 was found in 82% of gliomas. The alterations of the CDKN2A locus were also abundant in CHBs (62.5%) and PCC (75%), but p53 mutations were rare in these tumours. Our study supports the finding of other studies (5, 6, 32) that aberrant methylation of the p16 and p14 genes is highly important in PCC pathogenesis and for the first time reports a frequent inactivation of these genes in CHB.
CONCLUSIONS
The study contributes to the understanding of molecular pathways in the pathogenesis of poorly studied tumours -hemangioblastoma and pheochromocytoma -and shows a frequent inactivation of the genes p16 and p14 through aberrant methylation and genetic deletion in these tumours. In addition, our study supports data on the frequent involvement of the CDKN2A locus in the pathogenesis of gliomas -highly aggressive tumours of the CNS.
